Zobrazeno 1 - 10
of 5 623
pro vyhledávání: '"pazopanib"'
Autor:
Thi Thanh Cham Bui, Hue Linh Luu, Thi Thanh Luong, Thi Ngoc Nguyen, Nguyet Suong Huyen Dao, Van Giang Nguyen, Dinh Luyen Nguyen, Nguyen Trieu Trinh, Van Hai Nguyen
Publikováno v:
Chemistry, Vol 6, Iss 5, Pp 1089-1098 (2024)
Due to its application as an anti-cancer drug, pazopanib (1) has attracted the interest of many researchers, and several studies on pazopanib synthesis have been reported over the years. This paper provides a novel route for synthesizing N,2,3-trimet
Externí odkaz:
https://doaj.org/article/e79c8adcc1d74857b261e3baeab54ff6
Autor:
Ömer Faruk ELÇİÇEK, Mehmet KÜÇÜKÖNER
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 12, Iss 3, Pp 217-224 (2024)
Aim: We aimed to investigate the prognostic factors, factors affecting survival and the prognostic value of the Memorial Sloan-Kettering Cancer Centre (MSKCC) risk score in renal cell carcinoma (RCC) patients. In addition, we assessed the survival an
Externí odkaz:
https://doaj.org/article/dc1651bf3b994ed59bfff50c3a3f9d40
Publikováno v:
Advances in Human Biology, Vol 14, Iss 4, Pp 337-342 (2024)
Introduction: Undifferentiated round cell tumours (URCTs) are rare and less researched Ewing-like mesenchymal tumours that primarily affect bones and soft tissues. Therapeutic options for advanced URCT are limited. Pazopanib, a multi-tyrosine kinase
Externí odkaz:
https://doaj.org/article/8e72a9f4463e4413aaa7810f4fe12b44
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Pazopanib, which is dangerous for aquatic environments due to its toxic and bioaccumulation potential, has been detected at different concentrations in oncology hospital wastewater, sewage, and surface waters. This study aimed to remove pazo
Externí odkaz:
https://doaj.org/article/f444fb6ac7f7416585d7d60affe46e0a
Autor:
Zhijie Xu, Zhiyang Zhou, Xiaoxin Yang, Abhimanyu Thakur, Ning Han, Hai-Tao Li, Liu-Gen Li, Jun Hu, Tong-fei Li, Yuanliang Yan
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Pazopanib (PAZ), an oral multi-tyrosine kinase inhibitor, demonstrates promising cytostatic activities against various human cancers. However, its clinical utility is limited by substantial side effects and therapeutic resistance. We develop
Externí odkaz:
https://doaj.org/article/f5e4605a3ed24f9abc97e48608e701f5
Publikováno v:
Heliyon, Vol 10, Iss 19, Pp e38704- (2024)
Background: Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular tumor that accounts for less than 1 % of all vascular tumors. The diagnosis of primary hepatic epithelioid hemangioendothelioma (HEHE) can be challenging because it may
Externí odkaz:
https://doaj.org/article/2bf6e16a372541fa80f02e879d713606
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionPazopanib is a tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma and advanced soft-tissue sarcoma that functions by inhibiting vascular endothelial growth factor receptors. Although the package insert
Externí odkaz:
https://doaj.org/article/c05e03b8483c473db36d0b42ef9e08bb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown
Publikováno v:
Health Technology Assessment, Vol 28, Iss 45 (2024)
Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment
Externí odkaz:
https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7
Autor:
Jin-Ju Lei, Jie Rao, Hong-Yan Feng, De-Dong Cao, Hong-Lin Yan, Jing-Ping Yuan, Zhen-Min Jiang, Yi-Qiao Zhang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Thyroid-like follicular renal cell carcinoma (TLFRCC), also known as thyroid-like follicular carcinoma of the kidney or thyroid follicular carcinoma like renal tumor, is an exceedingly rare variant of renal cell carcinoma that has only recently been
Externí odkaz:
https://doaj.org/article/9ee003391797481b8be2355ebd534d8b